SEATTLE, Oct. 15 /PRNewswire/ — Omeros Corporation (Nasdaq:
OMER), a biopharmaceutical company committed to discovering,
developing and commercializing products focused on inflammation and
disorders of the central nervous system, today announced that
Gregory A. Demopulos, M.D., chairman and chief executive officer,
will present at the BioCentury NewsMakers in the Biotech Industry
Conference on October 22, 2010 at 1:30 p.m. Eastern time in New
York City. The presentation will be webcast. The live or archived
webcast can be accessed on the “Events” page of the Company’s
website at www.omeros.com.
About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed
to discovering, developing and commercializing products focused on
inflammation and disorders of the central nervous system. The
Company’s most clinically advanced product candidates are derived
from its proprietary PharmacoSurgery(TM) platform designed to
improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures. Omeros has five ongoing clinical
development programs, including four from its PharmacoSurgery(TM)
platform, the most advanced of which is in a Phase 3 clinical
program, and one from its Addiction program. Omeros may also have
the near-term capability, through its GPCR program, to add wholly
new drug targets to the market. Behind its clinical candidates and
GPCR platform, Omeros is building a diverse pipeline of antibody
and small-molecule preclinical programs targeting inflammation and
central nervous system disorders.
‘/>”/>
SOURCE
